Create your beautiful and unique blog. It's Free.

Latest Blogs - Health & Medicine




The “Prefilled Syringe Fill / Finish Service Providers, 2020-2030” report features an extensive study of the current market

Key Inclusions A detailed review of the overall landscape of companies offering contract fill / finish services for prefilled syringes, along with analyses based on a number of relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of the headquarters, location of fill / finish facilities, type of drug molecule (small molecule and biologic), syringe barrel material (glass and plastic), syringe fill volume and additional services offered (drug formulation, regulatory support, labelling and packaging, terminal sterilization, storage and logistics). In addition, the chapter includes details on prefilled syringe fill / finish installed capacity of the service providers. Tabulated profiles of key players (shortlisted based on a proprietary criterion) across key geographies, such as North America, Europe and Asia-Pacific. Each profile provides an overview of the company, information on its overall service portfolio, fill / finish facilities, financial performance (if available), and details on recent developments

Details

Over 100 companies across the globe claim to provide contract fill / finish services for prefilled syringes; close to 50% of these service providers are large companies with over 500 employees, claims Roots Analysis

According to the 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, biopharmaceutical manufacturers have been reported to outsource more than 30% of their fill / finish operations to contract service providers. Owing to the benefits, such as inherent safety and ease-of-use, and provisions to reduce dosing errors, risk of occlusions, extravasation and phlebitis, several injectable drugs (Humira®, Enbrel®, Avastin®, PREVNAR 13®, ALPROLIX® and Benefix®), diluents and other products requiring parenteral administration, are packaged in prefilled syringes.   To order this 260+ page report, which features 60+ figures and 110+ tables, please visit this link   The USD 3 billion (by 2030) financial opportunity within the prefilled syringe fill / finish services market has been analyzed across the following segments: Scale of Operation Preclinical / Clinical Commercial   Type of drug molecule Biologic Small Molecule   Target therapeutic area Blood disorders Infectious diseases Metabolic disorders Oncological

Details

The prefilled syringe fill / finish services market is projected to grow at an annualized rate of over 10%, till 2030

Roots Analysis has done a detailed study on Prefilled Syringe Fill / Finish Services Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 260+ page report, which features 60+ figures and 110+ tables, please visit this link   Key Market Insights Over 100 companies across the globe claim to provide contract fill / finish services for prefilled syringes; close to 50% of these service providers are large companies with over 500 employees. The market landscape features the presence of well- established players in the domain, most of which claim to operate at various scales of operation and are located in different geographies. In order to acquire competencies across the supply chain and cater to the evolving needs of clients, companies offering services across different scales of operation have established presence in various geographies. Fill / finish service providers are actively investing in expansion projects to upgrade existing capabilities and capacity; several partnerships,

Details

The prefilled syringe fill / finish services market is estimated to is estimated to reach close to USD 3 Billion by 2030

The numerous benefits offered by prefilled syringes, coupled to the growing self-medication trend, have led to the approval of a number of drugs in combination with such devices, resulting in an increase in need to outsource fill / finish operations   Roots Analysis is pleased to announce the publication of its recent study, titled, “Prefilled Syringe Fill / Finish Services Market, 2020-2030.”   The report features an extensive study of the current market landscape and future opportunities for contract service providers offering fill finish services for prefilled syringes. The study features an in-depth analysis of the key drivers and trends related to this evolving domain. Amongst other elements, the report includes: A detailed review of the overall landscape of companies offering contract fill / finish services for prefilled syringes  Tabulated profiles of key players (shortlisted based on a proprietary criterion) across key geographies, such as North America, Europe and Asia-Pacific. An analysis of the recent developments (since 2015) pertaining

Details

The ‘Patient Recruitment and Retention Services, 2019-2030’

Key Inclusions A detailed assessment of the current market landscape, including information on drug developer(s), A detailed assessment of the current market landscape of companies offering patient recruitment and retention services, including information on over 10 types of patient outreach methods employed, types of services offered ([A] patient recruitment (including pre-screening and Institutional Review Board (IRB) / Ethics Committee (EC) submission), [B] patient retention (considering various strategies, such as the use of study-branded gifts, study-branded reminders, providing education and support materials, reimbursement programs, transportation programs, patient engagement web site, patient reconnect programs, mobile applications to track patient engagement and others) and [C] other associated services (including site identification and selection, study feasibility / protocol development, project management, clinical trial monitoring and other services), year of establishment, geographical location, and size of company. The chapter also covers an analysis of the geographical

Details

Presently, close to 140 companies claim to be actively engaged in offering patient recruitment / retention services

A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed a significant burden on drug developer companies, prompting them to enlist the services of specialty service providers. Presently, close to 140 companies are actively offering patient recruitment and retention services. Majority of these players possess vast service portfolios and utilize diverse patient outreach methods to recruit study participants across different geographies and therapeutic indications.   To order this 300+ page report, which features 90+ figures and 140+ tables, please visit this link   The USD 5.3 billion (by 2030) financial opportunity within the patient recruitment and retention services market has been analyzed across the following segments: Therapeutic Area Oncology Infectious Diseases Cardiovascular Diseases CNS Disorders Respiratory Disorders Metabolic Disorders Others   Steps in Patient Recruitment Process Pre-screening Screening   Phase of Development Phase I Phase II Phase

Details

The patient recruitment and retention services market is projected to grow at an annualized rate of ~5%, till 2030

Roots Analysis has done a detailed study on Patient Recruitment and Retention Services Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 300+ page report, which features 90+ figures and 140+ tables, please visit this link   Key Market Insights Presently, close to 140 companies claim to be actively engaged in offering patient recruitment / retention services to the pharmaceutical and medical devices industries, employing a variety of outreach methods and solutions The market landscape is fragmented and distributed across various geographies; the growing need for specialized / niche study populations and cost saving options have made offshoring a popular trend Majority of the services providers are based in developed regions; the market is characterized by the presence of both established players and small-sized companies / new entrants Companies involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and comply

Details

The patient recruitment and retention services market is estimated to be worth USD 5.3

Roots Analysis  is pleased to announce the publication of its recent study, titled, “Patient Recruitment and Retention Services Marker, 2019-2030.”   The report offers a comprehensive study of the current scenario and future potential of the players providing patient enrollment and retention services. The study features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes: A detailed assessment of the current market landscape of companies offering patient recruitment and retention services. An analysis of the most active regions (in terms of patient recruitment activity) engaged in this domain, featuring schematic world map representations that highlight key hubs across the globe. An insightful 2X2 representation of the results of a competitiveness analysis of various service providers highlighting capable players in this domain, based on their respective capabilities. Comprehensive profiles of patient recruitment and retention service providers (shortlisted

Details

The “Oligonucleotide Synthesis, Modification and Purification Services Market

Key Inclusions A detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications. It features information on the year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with their locations (country-wise), and regulatory accreditations and certifications received by them, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites, and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, scale-up, fill/finish, downstream processing, regulatory support, data analytics and reporting, and others), type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes,

Details

More than 80 companies currently claim to offer manufacturing related services

Several big pharma companies are known to outsource more than half of their clinical-stage oligonucleotide manufacturing operations. Anticipating a sharp rise in demand, oligonucleotide manufacturers are increasingly consolidating their portfolios, building new capabilities and expanding their respective capacities, mostly through acquisitions, in order to gain a competitive edge.   To order this 300+ page report, which features 140+ figures and 190+ tables, please visit this link   The USD 5.8 billion (by 2030) financial opportunity within the oligonucleotide synthesis, modification and purification services market has been analyzed across the following segments: Type of manufacturing  Custom manufacturing Large-scale manufacturing   Type of Oligonucleotides manufactured Antisense Oligonucleotides miRNAs shRNAs siRNAs Other Oligonucleotides   Scale of operation Clinical Commercial   Purpose of production In-house Outsourced   Target therapeutic area Autoimmune Disorders Cardiovascular Disorders Genetic

Details

The oligonucleotide synthesis, modification and purification services market is projected

Roots Analysis has done a detailed study on “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 300+ page report, which features 140+ figures and 190+ tables, please visit this link   Key Market Insights More than 80 companies currently claim to offer manufacturing related services, at different scales of operations, for a variety of oligonucleotide-based products A wide range of services related to the synthesis, modification and purification of oligonucleotides, are currently offered within a fragmented service provider landscape that is mostly concentrated in the developed geographies In order to cater to the growing needs of clients / sponsors, companies have established presence across different regions; the US and some European nations have emerged as current hubs for oligonucleotide production Players involved in this domain are steadily

Details

The oligonucleotide synthesis, modification and purification services market

Roots Analysis is pleased to announce the publication of its recent study, titled, “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030.”   The report features an extensive study of the current scenario and future potential of the custom synthesis, modification and purification services market for oligonucleotides, which are intended for research, diagnostic, and therapeutic applications. The study includes in-depth analyses, highlighting the capabilities of service providers engaged in this domain. In addition to other elements, it includes: A detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications. A competitiveness analysis of prominent oligonucleotide manufacturers, featuring insightful pictorial summaries and representations. Elaborate profiles of key players that offer a diverse range of capabilities for custom synthesis, modification and purification of oligonucleotides. An

Details

The “Neoantigen Targeted Therapies Market, 2019-2030

Key Inclusions A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer. Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook. A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry. It also highlights the key

Details

Presently, over 150 neoantigen targeted therapies

The use of neoantigens in therapy has demonstrated the ability to elicit a strong T cell mediated immune response. Several therapy candidates are being investigated both as monotherapies and in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab, and nivolumab. Of these, certain pipeline candidates have already entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.   To order this 320+ page report, which features 110+ figures and 140+ tables, please visit this link     The USD 3 billion (by 2030) financial opportunity within the neoantigens market has been analyzed across the following segments: Type of target disease indication Bone cancer Colorectal cancer Gynecological cancer Non-small cell lung cancer Renal cell carcinoma Other cancers   Type of neoantigens Personalized neoantigens Off-the-shelf neoantigens   Type of immunotherapy Dendritic cell vaccines DNA / RNA-based vaccines Protein / peptide-based vaccines TIL-based

Details

The neoantigen targeted therapies market is projected to grow at an annualized rate of 57%,

Key Market Insights Presently, over 150 neoantigen targeted therapies are being evaluated for advanced cancer indications and are designed for delivery via different routes of administration Several molecules are in early stages of clinical development; based on delivery strategies, variety of vaccines and immunotherapies have been established for targeting personalized and shared antigens Over the years, more than 6,000 patents related to neoantigens and affiliated therapies have been granted / filed; this is indicative of the heightened pace of research in this field Both industry and academic players are contributing to the innovation, which is evident across published scientific literature focused on multiple targeted therapies for a myriad of cancer indications Several investors, having realized the untapped opportunity within this emerging segment of cancer immunotherapy, have invested over USD 7 billion across 150 instances in the period between 2014 and 2019 The increasing traction in this field is also reflected in the partnership activity; deals inked in the recent

Details

The neoantigen targeted therapies market is estimated to be worth USD 3 Billion in 2030

Roots Analysis is pleased to announce the publication of its recent study, titled, “Neoantigen Targeted Therapies, 2019-2030.”   The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: A detailed assessment of the current market landscape of developers engaged in the development of neoantigen targeted therapies. Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products). A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry. An in-depth analysis of the various patents that have been filed / granted related to neoantigens. An analysis of the various partnerships pertaining to neoantigen targeting

Details

The “In Silico / Computer-Aided Drug Discovery Services Market

  Key Inclusions A detailed review of the overall landscape of companies offering in silico drug discovery services for large molecules, including information on year of establishment, company size, location of headquarters, type of business model used (contract service providers (CROs), software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, antibody drug conjugates (ADCs), antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors and nucleic acids), type of in silico approach used (structure-based drug design (SBDD), fragment-based drug design (FBDD), target-based drug design (TBDD),

Details

Over 90 firms are actively involved in providing in silico services

Presently, in silico tools / approaches are available for the identification, selection and optimization of pharmacological leads. in fact, the predictive power of such solutions has been demonstrated to enable researchers to bypass the traditional experimental screening of billions of molecules against hundreds of biological targets, thereby, allowing significant reductions in the investment of both time and resources.   To order this 290+ page report, which features 120+ figures and 135+ tables, please visit this link   The USD 124 million (by 2030) financial opportunity within the in silico drug discovery market for large molecules has been analyzed across the following segments: Key Drug Discovery Steps Target Identification Target Validation Hit Generation Hit-to-Lead Lead Optimization   Type of Large Molecule Antibodies Proteins Peptides Nucleic Acids Vectors   Company Size Small Mid-sized Large   Target therapeutic Area Autoimmune Disorders Blood Disorders Cardiovascular Disorders Gastrointestinal and Digestive

Details

In silico drug discovery services market

Roots Analysis has done a detailed study on “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 290+ page report, which features 120+ figures and 135+ tables, please visit this link   Key Market Insights Over 90 firms are actively involved in providing in silico services for drug discovery of different types of biologics; of these, over 30 players claim to have the capabilities to offer services for all steps of discovery Majority of the companies offer structure-based drug design focused on early stage drug discovery of a range of large molecules, including antibodies, proteins and peptides Featuring the presence

Details

Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs

Key Inclusions A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.   Elaborate profiles of key players (established after 2005) that are engaged in the development of

Details
Page 1 of 296
FREE BLOG/SBM SITES
ads
ads
PropellerAds
Categories